Fact CheckerSign in

NCT07863336Not yet recruiting

ALSO-PERFORM Study. ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer

ALSO-PERFORM Study: ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer

Source: ClinicalTrials.gov · Last updated 8 Oct 2026

Brief summary (registry, in English)

Outcome of metastasis directed therapy

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
130 (estimated)
First submitted
1 Oct 2026
Start date
Jan 2027
Primary completion date
Dec 2027
Lead sponsor
Amsterdam UMC, location VUmc
NCT number
NCT07863336

What you commit to

  • Study type: Observational
  • Planned participants: 130
  • From Jan 2027 to the primary completion date, Dec 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous salvage radiotherapy to the prostate bed
  • Previous treatment in the pelvic region, such as treatment of the bladder or rectum, that precludes radiotherapy to the pelvis
  • Previous treatment with an LHRH agonist/antagonist within 6 months prior to study inclusion. Patients must have normal testosterone levels (testosterone \> 7.0 nmol/L)

Other

  • Men with lymph node metastases outside the pelvis (M1a)
  • Men with osseous metastases (M1b) or visceral metastases (M1c)
  • Men with lymphogenic metastases and a local recurrence
  • Men with inguinal metastases

Who the study is looking for

  • Men with histologically confirmed prostate cancer
  • Men who have undergone radical prostatectomy (RP), with or without extended pelvic lymph node dissection (ePLND)
  • Men with pNx or pN0 status in the ePLND specimen
  • Biochemical recurrence after RP (PSA \> 0.2 ng/mL on two occasions)
  • Evidence of lymphogenic metastases on staging PSMA PET/CT within the pelvis (below the aortic bifurcation)
  • Life expectancy ≥ 5 years, as estimated by the treating physician

Age in the registry: 18 years to 99 years · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.